Skip to content

Study · Case report or series · n = 1 · 2020

4 results

Efficacy of sodium-glucose cotransporter 2 inhibitor with glucagon-like peptide-1 receptor agonist for the glycemic control of a patient with Prader-Willi syndrome: a case report.

Sano H, Kudo E, Yamazaki T, Ito T, Hatakeyama K, Kawamura N

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology16 Apr 2020Cited by 9 (Europe PMC)

PMID32313377 (opens in a new tab)PMCIDPMC7160459 (opens in a new tab)DOI10.1297/cpe.29.81 (opens in a new tab)PepBankPUB-32313377
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a young woman with Prader-Willi syndrome and diabetes, glycemic control improved to a certain extent after liraglutide was introduced.

    In plain wordsIn one young woman with Prader-Willi syndrome and diabetes, blood sugar control improved somewhat after liraglutide was started.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGlycemic control after liraglutide introduction
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We present a diabetic female with PWS, whose glycemic control was deteriorated at the age of 19 but improved to a certain extent by introducing the GLP-1 analog liraglutide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a young woman with Prader-Willi syndrome and diabetes, HbA1c markedly decreased after empagliflozin was added to liraglutide.

    In plain wordsIn one young woman with Prader-Willi syndrome and diabetes, HbA1c fell markedly after empagliflozin was added to liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c after empagliflozin added to liraglutide
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Subsequently, her HbA1c level and body weight markedly decreased.
    1 context sentence
    Summary · context
    At the age of 20, the SGLT2 inhibitor empagliflozin was administered.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 03HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a young woman with Prader-Willi syndrome and diabetes, body weight markedly decreased after empagliflozin was added to liraglutide.

    In plain wordsIn one young woman with Prader-Willi syndrome and diabetes, body weight fell markedly after empagliflozin was added to liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight after empagliflozin added to liraglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Subsequently, her HbA1c level and body weight markedly decreased.
    1 context sentence
    Summary · context
    At the age of 20, the SGLT2 inhibitor empagliflozin was administered.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 04HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a young woman with Prader-Willi syndrome and diabetes, both insulin resistance and insulin secretion improved over six months after empagliflozin was added to liraglutide.

    In plain wordsIn one young woman with Prader-Willi syndrome and diabetes, insulin resistance and insulin release both improved over six months on liraglutide plus empagliflozin.

    Peptide
    Liraglutide
    Outcome
    MixedInsulin resistance and secretion after empagliflozin added to liraglutide
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Improvement in both insulin resistance and secretion was observed during the subsequent six months.
    1 context sentence
    Summary · context
    We present a diabetic female with PWS, whose glycemic control was deteriorated at the age of 19 but improved to a certain extent by introducing the GLP-1 analog liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.